Literature DB >> 18361386

Home therapy for lysosomal storage disorders.

Derryalynn A Hughes1, Alan Mlilligan, Atul Mehta.   

Abstract

Lysosomal storage disorders (LSDs) are a group of rare inherited metabolic disorders each resulting from the deficiency of a specific lysosomal enzyme and leading to the pathological accumulation of undegraded substrate. There are now several possible modalities of therapy for LSDs including intravenous enzyme replacement therapy (ERT). ERT is administered by intravenous infusion every week or 2 weeks. Therapy is lifelong and therefore a serious undertaking for patients and healthcare providers. Most patients will travel some distance to their specialist LSD centre and may therefore find frequent visits stressful, time-consuming and disruptive. The facility to administer enzyme replacement therapy in the home limits time spent at the hospital, restores independence and control of the disease to the patient, and reduces utilization of hospital resources and is associated with improved quality of life. A recent questionnaire survey indicates high levels of compliance with infusions in the home setting. Home therapy requires a well organized and regulated community infrastructure, individual assessments of patient suitability and protocols for management of possible infusion associated reactions.

Entities:  

Mesh:

Year:  2007        PMID: 18361386     DOI: 10.12968/bjon.2007.16.22.27768

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  9 in total

1.  Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families.

Authors:  R Freedman; M Sahhar; L Curnow; J Lee; H Peters
Journal:  J Genet Couns       Date:  2013-03-28       Impact factor: 2.537

2.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

3.  Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively.

Authors:  S Bagewadi; J Roberts; J Mercer; S Jones; J Stephenson; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2008-10-19       Impact factor: 4.982

Review 4.  Enzyme replacement and substrate reduction therapy for Gaucher disease.

Authors:  Elad Shemesh; Laura Deroma; Bruno Bembi; Patrick Deegan; Carla Hollak; Neal J Weinreb; Timothy M Cox
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

5.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

6.  Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group.

Authors:  D Concolino; L Amico; M D Cappellini; E Cassinerio; M Conti; M A Donati; F Falvo; A Fiumara; M Maccarone; R Manna; A Matucci; M B Musumeci; A Nicoletti; R Nisticò; F Papadia; R Parini; D Peluso; L Pensabene; A Pisani; G Pistone; M Rigoldi; I Romani; M Tenuta; G Torti; M Veroux; E Zachara
Journal:  Mol Genet Metab Rep       Date:  2017-06-22

7.  Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative.

Authors:  Derralynn A Hughes; Patricio Aguiar; Patrick B Deegan; Fatih Ezgu; Andrea Frustaci; Olivier Lidove; Aleš Linhart; Jean-Claude Lubanda; James C Moon; Kathleen Nicholls; Dau-Ming Niu; Albina Nowak; Uma Ramaswami; Ricardo Reisin; Paula Rozenfeld; Raphael Schiffmann; Einar Svarstad; Mark Thomas; Roser Torra; Bojan Vujkovac; David G Warnock; Michael L West; Jack Johnson; Mark J Rolfe; Sandro Feriozzi
Journal:  BMJ Open       Date:  2020-10-10       Impact factor: 2.692

8.  Home infusion with Elosulfase alpha (VimizimR) in a UK Paediatric setting.

Authors:  Niamh Finnigan; Jane Roberts; Jean Mercer; Simon A Jones
Journal:  Mol Genet Metab Rep       Date:  2017-11-05

Review 9.  Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.

Authors:  David Ah Whiteman; Alan Kimura
Journal:  Drug Des Devel Ther       Date:  2017-08-23       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.